wet age-related macular degeneration
Conditions
Interventions
1.0 mg Group:1.0mg conbercept injection
0.5mg Group:0.5mg conbercept injection
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged >=45 years old; 2. The patient was diagnosed as Wamd (including CNV, PCV) in our hospital after relevant examination (slit lamp, fundus photography, Oct, ERG, FFA, ICGA, etc.) and combined with clinical diagnosis; 3. The best corrected visual acuity of ETDRS was 0-73 letters. 4. The course of the disease was unlimited, and there was no refractive media turbidity and pupil reduction that affected fundus examination; 5. Sign the informed consent form and be willing to follow up according to the protocol.
Exclusion criteria
Exclusion criteria: 1. Subjects who voluntarily quit; 2. Patients who have used anti VEGF, laser photocoagulation, transpupillary thermotherapy, surgery and radiotherapy for the target eye or systemic system within three months before the trial; 3. The target eyes were treated with anti VEGF 3 times or more before the experiment; 4. The area of bleeding or exudation in the target eye was more than 6 optic discs; 5. The diameter of scar or fibrosis in the paraocular fovea was more than 500 uM; 6. The target eye is associated with other eye diseases (such as RVO, Rao, Dr, DME, CSC, etc.), excluding pathological myopia, cataract and other factors affecting refractive media; 7. There are diseases or conditions in the target eye or the whole body that the researchers think if the subjects continue to participate in this study, they may face greater risks (such as vitrectomy history, grade 3 hypertension, AIDS, malignant tumor, serious mental, cardiovascular, neurological, respiratory, digestive and other system diseases, or long-term hormone use, immune deficiency disease, heart stent surgery, organ Poor blood glucose control in diabetic patients; 8. The target eye has undergone intraocular or periocular surgery within 3 months (including laser photocoagulation near the central fovea, cataract surgery, etc.), except for the eyelid surgery which does not affect the vitreous injection (but the eyelid surgery cannot be performed within one month before the Administration); 9. The target eye had received corneal transplantation; 10. Cardiovascular events such as stroke, cerebral ischemia and myocardial infarction occurred in the first 6 months; 11. Those who do not use effective contraception; 12. In the course of the study, the researcher decided that it was not suitable to continue to participate in the experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCVA; | — |
Countries
China
Contacts
Public ContactSuqin Yu
Shanghai General Hospital
Outcome results
None listed